VEGFA and breast carcinoma: Another prospective study, which tested the impact of VEGF-A gene polymorphisms on the pharmacodynamics of first-line bevacizumab-containing therapy in 137 breast cancer patients, pointed out the potential role of VEGF-A polymorphisms.